Pruritic outcomes appear receptor- and dose-dependent: the non-selective agonist WIN55,212-2 reduced experimentally induced scratching via CB2 (blocked by SR144528 or CB2 knockout), whereas high-dose topical BCP induced dermatitis-like changes with pruritus in mice [36,133]. Here, CNR2 is linked to dermatitis.